mycosis fungoides cutaneous T-cell lymphoma
Dermatology · 2023–2023
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| chlormethine hydrochloride Treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients with no more than 25% body surface area involved who have failed, are… | Mar 2023 | Not recommended | 1 individuals Lymphoma Australia |
Who spoke
Lymphoma Australia
What the PBS pays
$0M in government benefit over 2024–25, across 128 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| chlormethine hydrochloride | $0.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.